{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:51:24Z","timestamp":1793332284991,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","award":["Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India"],"award-info":[{"award-number":["Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India"]}],"id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00213-025-06865-0","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T03:39:08Z","timestamp":1754537948000},"page":"601-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Montelukast attenuated memory decline, neuroinflammatory and neurodegenerative biomarkers in A\u03b21\u221242 exposed model of alzheimer\u2019s disease in mice"],"prefix":"10.1007","volume":"243","author":[{"given":"Sneha","family":"Balki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avtar Singh","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Gajanan","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awesh Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7834-6162","authenticated-orcid":false,"given":"Rakesh Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"6865_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020616","author":"MA Ahmad","year":"2022","unstructured":"Ahmad MA, Kareem O, Khushtar M, Akbar M, Haque MR, Iqubal A, Haider MF, Pottoo FH, Abdulla FS, Al-Haidar MB, Alhajri N (2022) Neuroinflammation: a potential risk for dementia. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23020616","journal-title":"Int J Mol Sci"},{"key":"6865_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0165-0270(90)90016-9","volume":"33","author":"A Alvarez-Buylla","year":"1990","unstructured":"Alvarez-Buylla A, Ling CY, Kirn JR (1990) Cresyl violet: a red fluorescent Nissl stain. J Neurosci Methods 33:129\u2013133","journal-title":"J Neurosci Methods"},{"key":"6865_CR3","volume":"1","author":"MS Benninger","year":"2009","unstructured":"Benninger MS, Waters H (2009) Montelukast: pharmacology, safety, tolerability and efficacy. Clin Med. Ther 1:CMT.S1147","journal-title":"Clin Med. Ther"},{"key":"6865_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3233\/JAD-143156","volume":"45","author":"DS Bouvier","year":"2015","unstructured":"Bouvier DS, Murai KK (2015) Synergistic actions of microglia and astrocytes in the progression of alzheimer\u2019s disease. J Alzheimers Dis 45:1001\u20131014","journal-title":"J Alzheimers Dis"},{"key":"6865_CR5","doi-asserted-by":"publisher","first-page":"856376","DOI":"10.3389\/fimmu.2022.856376","volume":"13","author":"Y Cai","year":"2022","unstructured":"Cai Y, Liu J, Wang B, Sun M, Yang H (2022) Microglia in the neuroinflammatory pathogenesis of Alzheimer\u2019s disease and related therapeutic targets. Front Immunol 13:856376","journal-title":"Front Immunol"},{"key":"6865_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bbi.2016.10.021","volume":"60","author":"F Chen","year":"2017","unstructured":"Chen F, Ghosh A, Wu F, Tang S, Hu M, Sun H, Kong L, Hong H (2017) Preventive effect of genetic knockdown and pharmacological blockade of CysLT1R on lipopolysaccharide (LPS)-induced memory deficit and neurotoxicity in vivo. Brain Behav Immun 60:255\u2013269","journal-title":"Brain Behav Immun"},{"key":"6865_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.bbi.2020.03.022","volume":"88","author":"F Chen","year":"2020","unstructured":"Chen F, Ghosh A, Lin J, Zhang C, Pan Y, Thakur A, Singh K, Hong H, Tang S (2020) 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer\u2019s disease. Brain Behav Immun 88:844\u2013855","journal-title":"Brain Behav Immun"},{"key":"6865_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","volume":"16","author":"J Cummings","year":"2021","unstructured":"Cummings J (2021) New approaches to symptomatic treatments for Alzheimer\u2019s disease. Mol Neurodegener 16:2","journal-title":"Mol Neurodegener"},{"key":"6865_CR9","doi-asserted-by":"crossref","unstructured":"Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, Taghva K (2022) Alzheimer\u2019s disease drug development pipeline: 2022. 8:e12295","DOI":"10.1002\/trc2.12295"},{"key":"6865_CR10","doi-asserted-by":"crossref","unstructured":"d\u2019Isa R, Brambilla R, Fasano S (2014) Behavioral methods for the study of the Ras-ERK pathway in memory formation and consolidation: passive avoidance and novel object recognition tests. Methods Mol Biol (Clifton NJ) 1120:131\u2013156","DOI":"10.1007\/978-1-62703-791-4_9"},{"key":"6865_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2174\/1871527320666210902163756","volume":"21","author":"AK Datusalia","year":"2022","unstructured":"Datusalia AK, Singh G, Yadav N, Gaun S, Manik M, Singh RK (2022) Targeted delivery of Montelukast for the treatment of Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 21:913\u2013925","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"6865_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1179\/1476830512Y.0000000019","volume":"15","author":"BF de Oliveira","year":"2012","unstructured":"de Oliveira BF, Veloso CA, Nogueira-Machado JA, de Moraes EN, dos Santos RR, Cintra MT, Chaves MM (2012) Ascorbic acid, alpha-tocopherol, and beta-carotene reduce oxidative stress and Proinflammatory cytokines in mononuclear cells of alzheimer\u2019s disease patients. Nutr Neurosci 15:244\u2013251","journal-title":"Nutr Neurosci"},{"key":"6865_CR13","doi-asserted-by":"crossref","unstructured":"Denninger JK, Smith BM, Kirby ED (2018) Novel object recognition and object location behavioral testing in mice on a budget. J Visualized Exp 141:e58593","DOI":"10.3791\/58593-v"},{"key":"6865_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12868-016-0280-9","volume":"17","author":"K Endres","year":"2016","unstructured":"Endres K, Reinhardt S, Geladaris A, Knies J, Grimm M, Hartmann T, Schmitt U (2016) Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice. BMC Neurosci 17:44","journal-title":"BMC Neurosci"},{"key":"6865_CR15","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.21037\/atm-21-4518","volume":"9","author":"SC Fang","year":"2021","unstructured":"Fang SC, Wang JJ, Chen F, Tang SS, Mu RH, Yuan DH, Zhao JJ, Hong H, Long Y (2021) Hippocampal CysLT1R overexpression or activation accelerates memory deficits, synaptic dysfunction, and amyloidogenesis in young APP\/PS1 Transgenic mice. Ann Transl Med 9:1531","journal-title":"Ann Transl Med"},{"key":"6865_CR16","doi-asserted-by":"publisher","first-page":"3454212","DOI":"10.1155\/2017\/3454212","volume":"2017","author":"P Gelosa","year":"2017","unstructured":"Gelosa P, Colazzo F, Tremoli E, Sironi L, Castiglioni L (2017) Cysteinyl leukotrienes as potential Pharmacological targets for cerebral diseases. Mediat Inflamm 2017:3454212","journal-title":"Mediat Inflamm"},{"key":"6865_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/cns.12596","volume":"22","author":"A Ghosh","year":"2016","unstructured":"Ghosh A, Chen F, Thakur A, Hong H (2016) Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders. CNS Neurosci Ther 22:943\u2013951","journal-title":"CNS Neurosci Ther"},{"key":"6865_CR18","doi-asserted-by":"publisher","first-page":"bpae015","DOI":"10.1093\/biomethods\/bpae015","volume":"9","author":"MH Hadwan","year":"2024","unstructured":"Hadwan MH, Hussein MJ, Mohammed RM, Hadwan AM, Saad Al-Kawaz H, Al-Obaidy SSM, Al Talebi ZA (2024) An improved method for measuring catalase activity in biological samples. Biol Methods Protoc 9:bpae015","journal-title":"Biol Methods Protoc"},{"key":"6865_CR19","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A (2021) The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry 26:5481\u20135503","journal-title":"Mol Psychiatry"},{"key":"6865_CR20","first-page":"3297","volume":"35","author":"Y Ishikura","year":"2021","unstructured":"Ishikura Y, Maeda-Minami A, Hosokawa M, Onoda A, Kawano Y, Ihara T, Sugamata M, Takeda K, Mano Y (2021) Leukotriene receptor antagonist use and dementia risk in patients with asthma: A retrospective cohort study. In Vivo (Athens Greece) 35:3297\u20133303","journal-title":"In Vivo (Athens Greece)"},{"key":"6865_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","volume":"53","author":"SH Jeong","year":"2023","unstructured":"Jeong SH, Jang JH, Lee YB (2023) Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Invest 53:119\u2013152","journal-title":"J Pharm Invest"},{"key":"6865_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.neuroscience.2010.08.039","volume":"171","author":"H Kalonia","year":"2010","unstructured":"Kalonia H, Kumar P, Kumar A, Nehru B (2010) Protective effect of Montelukast against quinolinic acid\/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-\u03b1 level alterations in rats. Neuroscience 171:284\u2013299","journal-title":"Neuroscience"},{"key":"6865_CR23","doi-asserted-by":"crossref","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia 4:575\u2013590","DOI":"10.1016\/j.trci.2018.06.014"},{"key":"6865_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.14283\/jpad.2023.109","volume":"10","author":"M Kiraly","year":"2023","unstructured":"Kiraly M, Foss JF, Giordano T (2023) Neuroinflammation, its role in Alzheimer\u2019s disease and therapeutic strategies. J Prev Alzheimers Dis 10:686\u2013698","journal-title":"J Prev Alzheimers Dis"},{"key":"6865_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/17476348.2016.1207533","volume":"10","author":"N Kittana","year":"2016","unstructured":"Kittana N, Hattab S, Ziyadeh-Isleem A, Jaradat N, Zaid A-N (2016) Montelukast, current indications and prospective future applications. Expert Rev Respir Med 10:943\u2013956","journal-title":"Expert Rev Respir Med"},{"key":"6865_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120994","volume":"607","author":"F Laffleur","year":"2021","unstructured":"Laffleur F, Bauer B (2021) Progress in nasal drug delivery systems. Int J Pharm 607:120994","journal-title":"Int J Pharm"},{"key":"6865_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.neuropharm.2014.01.011","volume":"79","author":"J Lai","year":"2014","unstructured":"Lai J, Hu M, Wang H, Hu M, Long Y, Miao MX, Li JC, Wang XB, Kong LY, Hong H (2014) Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates A\u03b21-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. Neuropharmacology 79:707\u2013714","journal-title":"Neuropharmacology"},{"key":"6865_CR28","doi-asserted-by":"publisher","first-page":"8712","DOI":"10.1039\/D4FO02602K","volume":"15","author":"VU Lasure","year":"2024","unstructured":"Lasure VU, Singh Gautam A, Singh RK (2024) Quercetin ameliorates neuroinflammatory and neurodegenerative biomarkers in the brain and improves neurobehavioral parameters in a repeated intranasal amyloid-beta exposed model of Alzheimer\u2019s disease. Food Funct 15:8712\u20138728","journal-title":"Food Funct"},{"key":"6865_CR29","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/alz.12610","volume":"18","author":"D Lecca","year":"2022","unstructured":"Lecca D, Jung YJ, Scerba MT, Hwang I, Kim YK, Kim S, Modrow S, Tweedie D, Hsueh SC, Liu D, Luo W, Glotfelty E, Li Y, Wang JY, Luo Y, Hoffer BJ, Kim DS, McDevitt RA, Greig NH (2022) Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. Alzheimers Dement J Alzheimers Assoc 18:2327\u20132340","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"6865_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1309482","volume":"18","author":"D Liu","year":"2024","unstructured":"Liu D, Lu J, Wei L, Yao M, Yang H, Lv P, Wang H, Zhu Y, Zhu Z, Zhang X, Chen J, Yang QX, Zhang B (2024) Olfactory deficit: a potential functional marker across the Alzheimer\u2019s disease continuum. Front Neurosci 18:1309482","journal-title":"Front Neurosci"},{"key":"6865_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2023.110025","volume":"402","author":"L Luijerink","year":"2024","unstructured":"Luijerink L, Rodriguez M, Machaalani R (2024) Quantifying GFAP immunohistochemistry in the brain\u2013 introduction of the reactivity score (R-score) and how it compares to other methodologies. J Neurosci Methods 402:110025","journal-title":"J Neurosci Methods"},{"key":"6865_CR32","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3390\/ph15091039","volume":"15","author":"CF Marques","year":"2022","unstructured":"Marques CF, Marques MM, Justino GC (2022) Leukotrienes vs. Montelukast-activity, metabolism, and toxicity hints for repurposing. Pharmaceuticals 15:1039","journal-title":"Pharmaceuticals"},{"key":"6865_CR33","doi-asserted-by":"publisher","first-page":"8466","DOI":"10.1038\/ncomms9466","volume":"6","author":"J Marschallinger","year":"2015","unstructured":"Marschallinger J, Sch\u00e4ffner I, Klein B, Gelfert R, Rivera FJ, Illes S, Grassner L, Janssen M, Rotheneichner P, Schmuckermair C, Coras R, Boccazzi M, Chishty M, Lagler FB, Renic M, Bauer HC, Singewald N, Bl\u00fcmcke I, Bogdahn U, Couillard-Despres S, Lie DC, Abbracchio MP, Aigner L (2015) Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. Nat Commun 6:8466","journal-title":"Nat Commun"},{"key":"6865_CR34","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s13311-020-00836-3","volume":"17","author":"J Marschallinger","year":"2020","unstructured":"Marschallinger J, Altendorfer B, Rockenstein E, Holztrattner M, Garnweidner-Raith J, Pillichshammer N, Leister I, Hutter-Paier B, Strempfl K, Unger MS, Chishty M, Felder T, Johnson M, Attems J, Masliah E, Aigner L (2020) The leukotriene receptor antagonist Montelukast reduces Alpha-Synuclein load and restores memory in an animal model of dementia with lewy bodies. Neurotherapeutics 17:1061\u20131074","journal-title":"Neurotherapeutics"},{"key":"6865_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.drudis.2018.09.008","volume":"24","author":"J Michael","year":"2019","unstructured":"Michael J, Marschallinger J, Aigner L (2019) The leukotriene signaling pathway: a druggable target in Alzheimer\u2019s disease. Drug Discov Today 24:505\u2013516","journal-title":"Drug Discov Today"},{"key":"6865_CR36","doi-asserted-by":"crossref","unstructured":"Michael J, Bessa de Sousa D, Conway J, Gonzalez-Labrada E, Obeid R, Tevini J, Felder T, Hutter-Paier B, Zerbe H, Paiement N, Aigner L (2020) Improved bioavailability of Montelukast through a novel oral Mucoadhesive film in humans and mice. Pharmaceutics 13:12","DOI":"10.3390\/pharmaceutics13010012"},{"issue":"5","key":"6865_CR37","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.3390\/ijms22052782","volume":"22","author":"J Michael","year":"2021","unstructured":"Michael J, Zirknitzer J, Unger MS, Poupardin R, Rie\u00df T, Paiement N, Zerbe H, Hutter-Paier B, Reitsamer H, Aigner L (2021) The leukotriene receptor antagonist Montelukast attenuates neuroinflammation and affects cognition in transgenic 5xFAD mice. Int J Mol Sci 22(5):2782.\u00a0https:\/\/doi.org\/10.3390\/ijms22052782","journal-title":"Int J Mol Sci"},{"key":"6865_CR38","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.ymthe.2020.02.005","volume":"28","author":"A Monaco","year":"2020","unstructured":"Monaco A, Maffia V, Sorrentino NC, Sambri I, Ezhova Y, Giuliano T, Cacace V, Nusco E, De Risi M, De Leonibus E, Schrader T, Kl\u00e4rner FG, Bitan G, Fraldi A (2020) The amyloid inhibitor CLR01 relieves autophagy and ameliorates neuropathology in a severe lysosomal storage disease. Mol Ther: J Am Soc Gene Ther 28:1167\u20131176","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"6865_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.neulet.2018.05.052","volume":"682","author":"VB Nagarajan","year":"2018","unstructured":"Nagarajan VB, Marathe PA (2018) Effect of Montelukast in experimental model of Parkinson\u2019s disease. Neurosci Lett 682:100\u2013105","journal-title":"Neurosci Lett"},{"key":"6865_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","volume":"95","author":"H Ohkawa","year":"1979","unstructured":"Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351\u2013358","journal-title":"Anal Biochem"},{"key":"6865_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12967-024-04908-2","volume":"22","author":"JD Pandya","year":"2024","unstructured":"Pandya JD, Musyaju S, Modi HR, Okada-Rising SL, Bailey ZS, Scultetus AH, Shear DA (2024) Intranasal delivery of mitochondria targeted neuroprotective compounds for traumatic brain injury: screening based on Pharmacological and physiological properties. J Transl Med 22:167","journal-title":"J Transl Med"},{"key":"6865_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213954","volume":"23","author":"E Passeri","year":"2022","unstructured":"Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A, Malaplate C, Yen FT, Arab-Tehrany E (2022) Alzheimer\u2019s disease: treatment strategies and their limitations. Int J Mol Sci 23:13954","journal-title":"Int J Mol Sci"},{"key":"6865_CR43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.bbrc.2017.01.052","volume":"484","author":"J Peng","year":"2017","unstructured":"Peng J, Zhou H, Kuang G, Xie L, Tian T, Liu R (2017) The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist Montelukast regulates extracellular matrix remodeling. Biochem Biophys Res Commun 484:474\u2013479","journal-title":"Biochem Biophys Res Commun"},{"key":"6865_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030588","volume":"14","author":"PC Pires","year":"2022","unstructured":"Pires PC, Rodrigues M, Alves G, Santos AO (2022) Strategies to improve drug strength in nasal preparations for brain delivery of low aqueous solubility drugs. Pharmaceutics 14:588","journal-title":"Pharmaceutics"},{"key":"6865_CR45","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejphar.2018.10.040","volume":"842","author":"SO Rahman","year":"2019","unstructured":"Rahman SO, Singh RK, Hussain S, Akhtar M, Najmi AK (2019) A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer\u2019s disease. Eur J Pharmacol 842:208\u2013220","journal-title":"Eur J Pharmacol"},{"key":"6865_CR46","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.crphar.2022.100149","volume":"4","author":"V Rani","year":"2023","unstructured":"Rani V, Verma R, Kumar K, Chawla R (2023) Role of pro-inflammatory cytokines in alzheimer\u2019s disease and neuroprotective effects of pegylated self-assembled nanoscaffolds. Curr Res Pharmacol Drug Discov 4:100149","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"6865_CR47","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s10787-024-01557-1","volume":"32","author":"V Sharma","year":"2024","unstructured":"Sharma V, Sharma P, Singh TG (2024) Leukotriene signaling in neurodegeneration: implications for treatment strategies. Inflammopharmacology 32:3571\u20133584","journal-title":"Inflammopharmacology"},{"key":"6865_CR48","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s10072-020-04369-7","volume":"41","author":"RK Singh","year":"2020","unstructured":"Singh RK (2020a) Antagonism of Cysteinyl leukotrienes and their receptors as a neuroinflammatory target in alzheimer\u2019s disease. Neurol Sci 41:2081\u20132093","journal-title":"Neurol Sci"},{"key":"6865_CR49","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2174\/1570159X18666200128121920","volume":"18","author":"RK Singh","year":"2020","unstructured":"Singh RK (2020b) Recent trends in the management of Alzheimer\u2019s disease: current therapeutic options and drug repurposing approaches. Curr Neuropharmacol 18:868\u2013882","journal-title":"Curr Neuropharmacol"},{"key":"6865_CR50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s43440-024-00692-4","volume":"77","author":"RK Singh","year":"2025","unstructured":"Singh RK (2025) Intranasal amyloid model of Alzheimer\u2019s disease - potential opportunities and challenges. Pharmacol Rep 77:425\u2013433","journal-title":"Pharmacol Rep"},{"key":"6865_CR51","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000312669","volume":"85","author":"RK Singh","year":"2010","unstructured":"Singh RK, Gupta S, Dastidar S, Ray A (2010) Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 85:336\u2013349","journal-title":"Pharmacology"},{"key":"6865_CR52","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neuropharm.2012.08.026","volume":"65","author":"S-S Tang","year":"2013","unstructured":"Tang S-S, Wang X-Y, Hong H, Long Y, Li Y-Q, Xiang G-Q, Jiang L-Y, Zhang H-T, Liu L-P, Miao M-X, Hu M, Zhang T-T, Hu W, Ji H, Ye F-Y (2013) Leukotriene D4 induces cognitive impairment through enhancement of CysLT1R-mediated amyloid-\u03b2 generation in mice. Neuropharmacology 65:182\u2013192","journal-title":"Neuropharmacology"},{"key":"6865_CR53","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.neurobiolaging.2013.09.036","volume":"35","author":"S-S Tang","year":"2014","unstructured":"Tang S-S, Hong H, Chen L, Mei Z-l, Ji M-j, Xiang G-q, Li N, Ji H (2014a) Involvement of cysteinyl leukotriene receptor 1 in A\u03b21\u201342-induced neurotoxicity in vitro and in vivo. Neurobiol Aging 35:590\u2013599","journal-title":"Neurobiol Aging"},{"key":"6865_CR54","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1017\/S1461145713001314","volume":"17","author":"S-S Tang","year":"2014","unstructured":"Tang S-S, Ji M-j, Chen L, Hu M, Long Y, Li Y-q, Miao M-x, Li J-c, Li N, Ji H, Chen X-j, Hong H (2014b) Protective effect of Pranlukast on A\u03b21\u201342-induced cognitive deficits associated with downregulation of Cysteinyl leukotriene receptor 1. Int J Neuropsychopharmacol 17:581\u2013592","journal-title":"Int J Neuropsychopharmacol"},{"key":"6865_CR55","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s43587-023-00404-2","volume":"3","author":"WM van der Flier","year":"2023","unstructured":"van der Flier WM, de Vugt ME, Smets EMA, Blom M, Teunissen CE (2023) Towards a future where Alzheimer\u2019s disease pathology is stopped before the onset of dementia. Nat Aging 3:494\u2013505","journal-title":"Nat Aging"},{"issue":"4","key":"6865_CR56","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mds.30144","volume":"40","author":"J Wallin","year":"2025","unstructured":"Wallin J, Forsberg A, Svenningsson P (2025) Effects of Montelukast on neuroinflammation in Parkinson\u2019s disease: an open label safety and tolerability trial with CSF markers and [(11)C]PBR28 PET. Mov Disord 40(4):739\u2013744","journal-title":"Mov Disord"},{"key":"6865_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/1567205016666191203153447","volume":"17","author":"Y Wang","year":"2020","unstructured":"Wang Y, Lv W, Li Y, Liu D, He X, Liu T (2020) Ampelopsin improves cognitive impairment in Alzheimer\u2019s disease and effects of inflammatory cytokines and oxidative stress in the hippocampus. Curr Alzheimer Res 17:44\u201351","journal-title":"Curr Alzheimer Res"},{"key":"6865_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nprot.2009.197","volume":"5","author":"CJ Weydert","year":"2010","unstructured":"Weydert CJ, Cullen JJ (2010) Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc 5:51\u201366","journal-title":"Nat Protoc"},{"key":"6865_CR59","doi-asserted-by":"publisher","first-page":"1161850","DOI":"10.3389\/fphar.2023.1161850","volume":"14","author":"M Wong-Guerra","year":"2023","unstructured":"Wong-Guerra M, Calfio C, Maccioni RB, Rojo LE (2023) Revisiting the neuroinflammation hypothesis in Alzheimer\u2019s disease: a focus on the druggability of current targets. Front Pharmacol 14:1161850","journal-title":"Front Pharmacol"},{"key":"6865_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13195-021-00892-7","volume":"13","author":"LY Xiong","year":"2021","unstructured":"Xiong LY, Ouk M, Wu CY, Rabin JS, Lanct\u00f4t KL, Herrmann N, Black SE, Edwards JD, Swardfager W (2021) Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer\u2019s dementia. Alzheimers Res Ther 13:147","journal-title":"Alzheimers Res Ther"},{"key":"6865_CR61","first-page":"100048","volume":"5","author":"V Yadav","year":"2024","unstructured":"Yadav V, Mythri C, Kumarasamy M (2024) Natural products as potential modulators of pro-inflammatory cytokines signalling in alzheimer\u2019s disease. Brain Behav Immun Integr 5:100048","journal-title":"Brain Behav Immun Integr"},{"key":"6865_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12974-022-02625-5","volume":"19","author":"AG Yates","year":"2022","unstructured":"Yates AG, Kislitsyna E, Alfonso Martin C, Zhang J, Sewell AL, Goikolea-Vives A, Cai V, Alkhader LF, Skaland A, Hammond B, Dimitrova R, Batalle D, Fernandes C, Edwards AD, Gressens P, Thornton C, Stolp HB (2022) Montelukast reduces grey matter abnormalities and functional deficits in a mouse model of inflammation-induced encephalopathy of prematurity. J Neuroinflammation 19:265","journal-title":"J Neuroinflammation"},{"key":"6865_CR63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/aps.2013.130","volume":"35","author":"SY Yu","year":"2014","unstructured":"Yu SY, Zhang XY, Wang XR, Xu DM, Chen L, Zhang LH, Fang SH, Lu YB, Zhang WP, Wei EQ (2014) Cysteinyl leukotriene receptor 1 mediates LTD4-induced activation of mouse microglial cells in vitro. Acta Pharmacol Sin 35:33\u201340","journal-title":"Acta Pharmacol Sin"},{"key":"6865_CR64","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12974-019-1658-2","volume":"16","author":"H Zeng","year":"2019","unstructured":"Zeng H, Liu N, Yang Y-y, Xing H-y, Liu X-x, Li F, La G-y, Huang M-j, Zhou M-w (2019) Lentivirus-mediated downregulation of \u03b1-synuclein reduces neuroinflammation and promotes functional recovery in rats with spinal cord injury. J Neuroinflamm 16:283","journal-title":"J Neuroinflamm"},{"key":"6865_CR65","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L (2024) Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9:211","journal-title":"Signal Transduct Target Ther"},{"key":"6865_CR66","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.2042-7158.2010.01238.x","volume":"63","author":"R Zhao","year":"2011","unstructured":"Zhao R, Shi WZ, Zhang YM, Fang SH, Wei EQ (2011) Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. J Pharm Pharmacol 63:550\u2013557","journal-title":"J Pharm Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06865-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:02:44Z","timestamp":1773216164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06865-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["6865"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06865-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the procedures and protocols were approved by Institutional Animal Ethics Committee (IAEC) of NIPER-Raebareli, Lucknow, India (protocol number NIPER\/RBL\/IAEC\/135\/June 2023) and used in the experiment as per the provisions laid down by the Committee for Control and Supervision of Experiments on Animals (CCSEA), India.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}